Skip to main content
Displaying 1 - 12 of 30
Display:
12
24
48
Metabolism, Alcohol & Toxicity
1
GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
1
GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
8
Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
Boehringer Ingelheim: MASH in focus: novel insights on diagnosis, management and coordinated patient care - EASL Congress 2024
View
Pagination
Current page
1
Page
2
Page
3
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy